Novo Nordisk accelerates clinical documentation and drug development with Claude
Accelerate science, from discovery through translation
Claude helps pharma companies, biotech startups, and research institutions move faster, while maintaining the accuracy your work demands.
Built for breakthrough science
AI you can trust
Claude models are safe, secure, and reliably accurate, so you can handle clinical trial data and proprietary compounds with confidence.
Built for scientific complexity
Analyze genomic data, synthesize findings across hundreds of papers, and design experiments with full citations. Claude matches the complexity of modern drug development.
Made for R&D
Claude connects to Benchling, PubMed, 10x Genomics, and your lab platforms—so every scientist can accelerate their work from discovery through regulatory submission.
Your partner in discovery
We collaborate with pharma leaders and research institutions to make sure Claude evolves with the needs of life sciences and advances real scientific discovery.

Tune in to watch Anthropic CEO and Co-founder Dario Amodei share his vision for AI in healthcare and life sciences, along with an executive customer panel.
How life sciences teams use Claude
Phase 2 Clinical Trial Protocol
ABX-7291 for Treatment of Parkinson's Disease | DRAFT v0.1
Study Synopsis
Protocol Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABX-7291 in Patients with Early-Stage Parkinson's Disease
Sponsor: [Sponsor Name]
Phase: Phase 2
Indication: Early-stage Parkinson's Disease (Hoehn & Yahr Stage 1-2)
Study Duration: 24 weeks treatment + 4 weeks follow-up
Objectives and Endpoints
Primary Objective
Evaluate the efficacy of ABX-7291 compared to placebo in reducing motor symptoms in patients with early-stage Parkinson's disease.
Primary Endpoint
Change from baseline in MDS-UPDRS Part III (Motor Examination) score at Week 24.
Secondary Endpoints
- Change from baseline in MDS-UPDRS Total Score at Week 24
- Proportion of patients achieving ≥30% improvement in MDS-UPDRS Part III
- Change in PDQ-39 (Quality of Life) score at Week 24
- Safety and tolerability (AEs, laboratory parameters, vital signs)
Study Design
This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group study. Eligible patients will be randomized 1:1:1 to receive ABX-7291 low dose, ABX-7291 high dose, or placebo for 24 weeks.
Sample Size and Rationale
Total Enrollment: 120 patients (40 per arm)
Statistical Power: 80% power at α=0.05 (two-sided)
Expected Effect Size: 5-point difference in MDS-UPDRS Part III (SD=8)
Dropout Assumption: 15% (based on comparable Phase 2 PD trials)
Rationale: Sample size derived from analysis of 12 comparable Phase 2 trials on ClinicalTrials.gov with similar indications and endpoints.
Regulatory References
- 21 CFR 312 (Investigational New Drug Application)
- FDA Guidance: Parkinson's Disease: Developing Drugs for Treatment (2023)
- ICH E6(R2): Good Clinical Practice
- ICH E9: Statistical Principles for Clinical Trials
Generated using Clinical Protocol Generation skill
Sources: ClinicalTrials.gov (12 comparable studies), FDA guidance documents
Ready for review with biostatisticians and regulatory affairs

Protocol generation
Draft study protocols, SOPs, and consent documents directly in Benchling. Claude structures experimental workflows while you maintain control over scientific decisions.

Research synthesis
Survey hundreds of papers in hours instead of weeks. Claude synthesizes findings across biomedical literature, identifies contradictions, and generates testable hypotheses with verifiable citations.
- Now let me run the QC analysis on the raw feature matrix:
- Bash(python3 scripts/qc_analysis.pypbmc_test_data/raw_feature_bc_matrix.h5)
↳===========================================================
Single-Cell RNA-seq Quality Control AnalysisFollowing scVerse Best Practices
… +60 lines (ctrl+o to expand)
- Excellent! The QC analysis completed successfully. Let me update the visualizations:
- Read(qc_metrics_before_filtering.png)↳ Read image (732.3KB)
- Read(qc_filtering_thresholds.png)↳ Read image (210KB)
- Read(qc_metrics_after_filtering.png)↳ Read image (1.1MB)
- Perfect! I've successfully completed the QC analysis on your raw feature matrix using the scRNA-qc skill. Here's a summary of the results:QC Analysis SummaryDataset: 2,700 cells × 32,738 genes (raw)Quality Metrics Detected:
- 13 mitochondrial genes
- 106 ribosomal genes
- 13 hemoglobin genes
- Total counts: 709 - 6,812
- Genes detected: 367 - 1,821
- Mitochondrial %: MAD threshold 3.65%, Hard threshold 8.0%
- 266 cells removed as outliers (9.9%)
- 2,434 cells retained (90.1%)
- Gene filtering reduced from 32,738 to 9,487 genes (29.0%)
- Before Filtering: The data shows typical scRNA-seq quality with most cells having 1,000-2,000 counts and detecting 500-1,000 genes. Mitochondrial content is generally low (<5%), which is excellent.
- Thresholds: The MAD-based thresholds are permissive (5 MADs for counts/genes, 3 MADs for MT%), following scverse best practices to avoid over-filtering.
- After Filtering: The filtered dataset shows cleaner distributions with tighter clustering, lower mitochondrial content (mostly <3%), and good cell-gene correlation.
- raw_feature_bc_matrix_filtered.h5ad - Clean filtered dataset ready for downstream analysis
- raw_feature_bc_matrix_with_qc.h5ad - Original data with QC annotations
- QC visualization PNGs (before/thresholds/after)


Bioinformatics and data analysis
Process genomic data and optimize analysis workflows with Claude Code. Claude presents results clearly so you can easily communicate with cross-functional teams.
Clinical Safety Summary
Module 2.7.4 | IND-2024-0892
Study Overview
Drug: ABX-4721 (anti-inflammatory biologic)
Phase: Phase 1
Subjects: 48 healthy volunteers
Duration: 12-week duration
Adverse Event Summary
Total subjects with AEs: 23 (47.9%)
Serious adverse events: 2 (4.2%)
Discontinuations due to AEs: 1 (2.1%)
Deaths: 0
Safety Signals for Phase 2 Monitoring
⚠ Hepatic
Elevated ALT (>3x ULN): 3 subjects (6.3%)
All resolved without intervention within 14 days
→ Recommend: LFT monitoring at weeks 2, 4, 8
⚠ Injection site reactions
Mild erythema: 8 subjects (16.7%)
No treatment required
→ Recommend: Document severity grading in Phase 2
Regulatory References
- 21 CFR 312.32 (IND Safety Reporting)
- ICH E2A: Clinical Safety Data Management
- FDA Guidance: Premarketing Risk Assessment
Generated from uploaded AE reports and lab data
All source documents linked for audit trail

Clinical and regulatory strategy and compliance
Generate regulatory summaries and compile safety data across modules with full audit trails. Focus on scientific decisions, not document formatting.












Claude connects to your research ecosystem
Literature, lab notebooks, analysis platforms, all working together in one place.
Get started with Claude
Pro
- Life sciences connectors and skills
- Access to file creation (docs, slides, spreadsheets, and PDFs)
- Access to research
- Access to Claude Code
- Life sciences guides and docs
Max
- Choose 5x or 20x more usage than Pro*
- Higher output limits for all tasks
- Early access to advanced Claude features
Additional usage limits apply. Prices shown don’t include applicable tax.
Team
- For organizations purchasing fewer than 20 seats
- Life sciences connectors and skills
- Access to file creation (docs, slides, spreadsheets, and PDFs)
- Single sign-on (SSO)
- Central billing and administration
- Claude Code available with premium seats
- Life sciences guides and docs
Enterprise
- More usage*
- HIPAA-ready infrastructure (added cost)
- Enhanced context window
- Compliance API for observability and monitoring
- Single sign-on (SSO) and domain capture
- Custom data retention controls
Additional usage limits apply. Prices shown don’t include applicable tax.